MindRank is an AI-powered biotechnology company.
To transform drug discovery and development by continuously inventing and integrating innovations across machine learning, biology and chemistry.
Our ultimate goal is to find better drugs, treat more diseases, and help more patients.
Focusing on Difficult-to-Drug Molecular Targets
In addition to speeding up and reducing costs of drug discovery, we aim to discover innovative therapies and new chemical spaces.
2021Our former AI solution was selected for funding (multi-million EURO) by the 2020 “Europe Innovative Medicines Initiative” to combat coronavirus
FebPartnership with a listed Biotechnology company (undisclosed)
MarOur proprietary AI solution was nominated by Deep Pharma Intelligence as one of the 11 "Top AI Breakthroughs in Biopharma from 2018 to 2020"
MayRaised $7M Seed Funding from Sherpa Healthcare Partners
JunThe AI team won 1st place in the "Global Artificial Intelligence Technology Innovation Contest" hosted in Hangzhou, China
JulDelivered an allosteric inhibitor PCC with Best-in-Class potential to a public traded biotech company
AugPartnership with Antengene (HK:6996) on AI-enabled Drug Discovery
OctPartnership with Medicilon (SHA:688202) on AI-enabled Drug Discovery
DecTens of millions US dollar Series A Funding
- AI drug discovery paper published in Nature Biomedical Engineering
- Partnership with Chemexpress (SHA:688131) strengthened in AI-enabled Synthetic Accessibility
- Mindrank's AI-designed proprietary small molecule drug began IND-enabling studies, eight months after program initiation